Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Rating of "Hold" from Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.00.

Several brokerages recently weighed in on VRCA. Wall Street Zen raised Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright reissued a "neutral" rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, May 14th.

Verrica Pharmaceuticals Price Performance

NASDAQ:VRCA traded down $0.02 during mid-day trading on Thursday, reaching $0.60. The company's stock had a trading volume of 74,112 shares, compared to its average volume of 362,217. The company's fifty day simple moving average is $0.51 and its two-hundred day simple moving average is $0.67. Verrica Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $9.36. The stock has a market cap of $55.03 million, a P/E ratio of -0.33 and a beta of 1.73.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The firm had revenue of $3.44 million for the quarter, compared to analysts' expectations of $2.53 million. Sell-side analysts expect that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VRCA. Caligan Partners LP acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter worth approximately $5,201,000. Boothbay Fund Management LLC acquired a new position in Verrica Pharmaceuticals in the fourth quarter worth approximately $1,811,000. Geode Capital Management LLC grew its position in Verrica Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock worth $334,000 after buying an additional 21,789 shares during the last quarter. Sovran Advisors LLC bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $267,000. Finally, Heights Capital Management Inc. bought a new stake in shares of Verrica Pharmaceuticals during the 4th quarter worth $246,000. Institutional investors own 42.45% of the company's stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.